Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Show more

30 Technology Drive, Warren, NJ, 07059, United States

Drug Manufacturers - Specialty & Generic
Healthcare
Start AI Chat

Market Cap

484.4M

52 Wk Range

$2.12 - $7.55

Previous Close

$3.97

Open

$3.97

Volume

2,433,174

Day Range

$3.89 - $4.10

Enterprise Value

677.7M

Cash

129.1M

Avg Qtr Burn

-12.65M

Insider Ownership

3.37%

Institutional Own.

62.06%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Exservan™ (riluzole) Oral Film Details
Amyotrophic Lateral Sclerosis (ALS)

Approved

Quarterly sales

KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details
Parkinson’s disease (OFF Episodes / motor fluctuations)

Approved

Quarterly sales

NDA

Resubmission

IND

Submission

AQST-119 Details
Erectile dysfunction

Failed

Discontinued